SANTA CRUZ BIOTECHNOLOGY, INC.

FLIP_L (C-19): sc-7108



BACKGROUND

FLIP (FLICE inhibitory protein) is expressed as both long and short forms and is involved in the regulation of apoptosis. The short form of FLIP contains two death effector domains homologous to the death effector domain of the FAS-associating protein FADD. The long form of FLIP, which shares significant homology with the cysteine protease FLICE, contains an additional caspaselike domain, but lacks a catalytic active site and lacks the residues that form the substrate binding pocket in most caspases. FLIP has been designated by independent groups as Casper, I-FLICE, CLARP, FLAME-1 and MRIT. Although its exact role is still being elucidated, FLIP appears to be an important factor in the regulation of apoptosis downstream of all known death receptors.

REFERENCES

- 1. Thome, M., et al. 1997. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 386: 517-521.
- 2. Irmler, M., et al. 1997. Inhibition of death receptor signals by cellular FLIP. Nature 388: 190-195.
- Shu, H.B., et al. 1997. Casper is a FADD- and caspase-related inducer of apoptosis. Immunity 6: 751-763.

CHROMOSOMAL LOCATION

Genetic locus: CFLAR (human) mapping to 2q33.1.

SOURCE

 $FLIP_L$ (C-19) is an affinity purified goat polyclonal antibody raised against a peptide mapping at the C-terminus of $FLIP_1$ of human origin.

PRODUCT

Each vial contains 200 μg lgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-7108 P, (100 μ g peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

APPLICATIONS

 $FLIP_L$ (C-19) is recommended for detection of $FLIP_L$ of human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000); non cross-reactive with $FLIP_S$.

 $\ensuremath{\mathsf{FLIP}}_L$ (C-19) is also recommended for detection of $\ensuremath{\mathsf{FLIP}}_L$ in additional species, including canine.

Suitable for use as control antibody for $\text{FLIP}_{S/L}$ siRNA (h): sc-35388, $\text{FLIP}_{S/L}$ siRNA (h) Plasmid: sc-35388-SH and $\text{FLIP}_{S/L}$ siRNA (h) Lentiviral Particles: sc-35388-V.


Molecular Weight of FLIP_L: 55 kDa.


Positive Controls: FLIPS/L (h2): 293T Lysate: sc-170479, TF-1 cell lysate: sc-2412 or HeLa whole cell lysate: sc-2200.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

DATA





 $FLIP_L$ (C-19): sc-7108. Western blot analysis of $FLIP_L$ expression in MIA PaCa-2 (A), A-431 (B), TF-1 (C) and JAR (D) whole cell lysates.

<code>FLIP_(M-18): sc-7108. Western blot analysis of FLIP_expression in non-transfected 293T: sc-117752 (A), human FLIP_{S/L} transfected 293T: sc-170479 (B) and HeLa (C) whole cell lysates.</code>

SELECT PRODUCT CITATIONS

- Jurewicz, A., et al. 2005. Tumour necrosis factor-induced death of adult human oligodendrocytes is mediated by apoptosis inducing factor. Brain 128: 2675-2688.
- 2. Horak, P., et al. 2005. Perturbation of the tumor necrosis factor-related apoptosis-inducing ligand cascade in ovarian cancer: overexpression of FLIP_L and deregulation of the functional receptors DR4 and DR5. Clin. Cancer Res. 11: 8585-8591.
- Gravina, G.L., et al. 2010. 5-Azacitidine restores and amplifies the bicalutamide response on preclinical models of androgen receptor expressing or deficient prostate tumors. Prostate 70: 1166-1178.
- Anees, M., et al. 2011. Recurrence-free survival in prostate cancer is related to increased stromal TRAIL expression. Cancer 117: 1172-1182.
- Sung, W.W., et al. 2011. A polymorphic -844T/C in FasL promoter predicts survival and relapse in non-small cell lung cancer. Clin. Cancer Res. 17: 5991-5999.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.

